Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 2002

View Archived Issues

DB-289 enters phase II trial for PCP in HIV/AIDS patients

Third phase III trial under way for INS-365 Ophthalmic in dry eye

Promising profile reported at AACR meeting for novel histone deacetylase inhibitor CG-1521

LAQ-824: a potential new antitumor agent acting via inhibition of histone deacetylase

Novel RXR agonist characterized at ACS meeting by GSK

Flt-3 kinase inhibitors and potential for treatment of AML discussed in Orlando by Millennium

Favorable pharmacokinetic profile seen for novel tyrosine kinase inhibitor CHIR-200131

Orally active VEGF receptor tyrosine kinase-selective agent presented at AACR meeting

Independent review and long-term follow-up of phase II Orathecin study

ACS news: Abbott describes discovery of new series of PTP1B inhibitors

Potent, selective, nonpeptide PTP1B inhibitors discovered in Novo Nordisk/Ontogen joint effort

Adherex and AstraZeneca extend Exherin collaboration agreement

European Commission designates E21R orphan drug in JMML

IAVI-sponsored AIDS vaccines enter phase II

Gliatech receives grant for selective GlyT1 inhibitor development

Collateral updates achievements of 2001

Preclinical data discussed this week support clinical trials with thioplatin

WX-G250 and WX-G250RIT designated orphan drugs for renal cell carcinoma in E.U.

Inhibitors of uPA with favorable PK properties described in patent literature

New vascular damaging agents in development at Angiogene Pharmaceuticals

Neurogen patents new series for CNS disorders

Potent and selective uPA inhibitors designed by Corvas scientists

Streptomyces strain discovered to produce new antitumor compounds

Antiherpesvirus agents jointly prepared by Pfizer and JT

Japan Tobacco patents analgesic thiazole compounds

Gene-based therapy EG-009 designated orphan drug for high-grade glioma

FDA approves SecreFlo for diagnosis of pancreatic dysfunction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...